CHICAGO (GenomeWeb) – Diagnostic decision support company Variantyx is betting on two notions: that clinicians need help sorting through genomic data from next-generation sequencing and that the trend is toward whole-genome sequencing.
"We feel like the future is going to be about whole genomes," said Muthu Meyyappan, chief commercial officer of the Framingham, Massachusetts-based vendor.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
